Experience of combined antihypertensive therapy in patients with metabolic syndrome

Metabolic syndrome (MS) is a complex of risk factors for cardiovascular diseases and type 2 diabetes mellitus (DM). The main components of MS are arterial hypertension (AH), obesity, disorders of carbohydrate and lipid metabolism. Currently, in most countries of the world, there is a tendency for an increase in the incidence of MS. The prognostic value of MS is determined by the powerful influence of numerous cardiovascular risk factors, the correction of which seems to be an important area of therapeutic and prophylactic measures. There is no doubt about the thesis that the correction of blood pressure (BP) in MS should be carried out in parallel with careful control of plasma glucose levels, total cholesterol, body weight and other risk factors.